Complete Response to tenalisib and romidepsin with long-term maintenance using tenalisib monotherapy in a patient with relapsed and refractory sézary syndrome

Invest New Drugs. 2023 Apr;41(2):350-355. doi: 10.1007/s10637-022-01315-6. Epub 2023 Apr 1.

Abstract

Mycosis fungoides (MF) and Sézary Syndrome (SS) are the most common subtypes of cutaneous T cell lymphomas (CTCL). Advanced-stage MF/SS have poor prognoses and may be refractory to multiple systemic treatments. These cases can be difficult to achieve and maintain complete response and there is a need for novel therapeutics. Inhibition of the phosphatidylinositol 3-kinase (PI3K) pathway by Tenalisib presents one such emerging drug. We report a relapsed/refractory SS patient achieving complete remission using the combination of Tenalisib and Romidepsin and subsequently maintaining long-duration CR with Tenalisib monotherapy.

Keywords: Cutaneous T Cell Lymphoma; Mycosis Fungoides; Refractory; Sézary Syndrome.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Humans
  • Lymphoma, T-Cell, Cutaneous* / drug therapy
  • Phosphatidylinositol 3-Kinases
  • Sezary Syndrome* / drug therapy
  • Sezary Syndrome* / pathology
  • Skin Neoplasms* / drug therapy
  • Skin Neoplasms* / pathology

Substances

  • romidepsin
  • tenalisib
  • Phosphatidylinositol 3-Kinases